Shivajirao N. Thore

: Coronavirus disease 2019 (Covid-19), a serious disease caused by the Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2), was firstly identified in the city of Wuhan of China in December 2019, which then spread and became a global issue due to its high transmission rate. To date, the outbreak of COVID-19 has resulted in infection to 230,868,745 people and the death of 4,732,669 patients. It has paralyzed the economy of all the countries worldwide. Considering the possible mutations of SARS-CoV-2, the current medical emergency requires a longer time for drug design and vaccine development. Drug repurposing is a promising option for potent therapeutics against the pandemic. The present review encompasses various drugs or appropriate combinations of already FDA-approved antimalarial, antiviral, anticancer, anti-inflammatory, and antibiotic therapeutic candidates for use in the clinical trials as a ray of hope against COVID-19. It is expected to deliver better clinical and laboratory outcomes of drugs as a prevention strategy for the eradication of the disease.

SYNTHESIS AND ANTI-PROLIFERATIVE SCREENING OF NEW THIAZOLE COMPOUNDS

A simple, expeditious and green process for Knoevenagel condensation of pyrazole aldehydes in aqueous media

Triazolo[4,3‐a]tetrahydrobenzo(b)thieno[3,2‐e]pyrimidine‐5(4H)‐ones (5a,5b,5c,5d,5e,5f,5g,5h,5i,5j,5k,5l,5mwere synthesized and characterized by spectral analysis. All 13 derivatives were evaluated for central nervous system (CNS) depressant and skeletal muscle relaxant activities in Swiss albino mice. All the activities were compared with diazepam as a standard drug at a dose of 5 mg/kg. The most active derivatives5d,5e,5k, and5lin CNS depressant and skeletal muscle relaxant activities were selected for anticonvulsant activity. The active derivatives were found to protect 100% mice at the dose of 6–11 mg/kg, where as standard diazepam protect the animal at a dose of 2.5 mg/kg.